Published in J Virol on July 11, 2012
Evasion of influenza A viruses from innate and adaptive immune responses. Viruses (2012) 1.06
Impaired heterologous immunity in aged ferrets during sequential influenza A H1N1 infection. Virology (2014) 0.80
Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza. Front Immunol (2015) 0.79
Prevalence of the C-terminal truncations of NS1 in avian influenza A viruses and effect on virulence and replication of a highly pathogenic H7N1 virus in chickens. Virulence (2016) 0.79
Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol (2014) 0.76
Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA. J Control Release (2015) 0.75
A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine. J Virol (2016) 0.75
Reverse Genetics Approaches for the Development of Influenza Vaccines. Int J Mol Sci (2016) 0.75
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) (2016) 0.75
Changing risk awareness and personal protection measures for low to high pathogenic avian influenza in live-poultry markets in Taiwan, 2007 to 2012. BMC Infect Dis (2015) 0.75
CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice. PLoS One (2016) 0.75
From Variation of Influenza Viral Proteins to Vaccine Development. Int J Mol Sci (2017) 0.75
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine (2005) 5.55
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity (2001) 5.04
Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol (2006) 4.55
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A (2000) 3.95
New low-viscosity overlay medium for viral plaque assays. Virol J (2006) 3.92
Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 3.81
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med (2008) 3.15
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis (2009) 2.68
Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci U S A (1996) 2.54
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine (2007) 2.51
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine (2002) 2.47
Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol (2006) 2.38
Type I IFN modulates innate and specific antiviral immunity. J Immunol (2000) 2.26
Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med (2004) 2.23
Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol (2009) 2.08
Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol (2009) 2.00
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Why aging T cells fail: implications for vaccination. Immunity (2006) 1.78
Unraveling the mystery of swine influenza virus. Cell (2009) 1.70
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med (2006) 1.68
Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res (2009) 1.67
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis (1993) 1.62
Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br J Dermatol (2002) 1.59
Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol (2009) 1.50
Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine (2007) 1.45
Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology (1991) 1.44
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Influenza: evolving strategies in treatment and prevention. Semin Respir Crit Care Med (2007) 1.44
Challenges for vaccination in the elderly. Immun Ageing (2007) 1.42
Immune response to influenza vaccination in a large healthy elderly population. Vaccine (1999) 1.41
The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol (2004) 1.39
Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity (2009) 1.38
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis (2010) 1.18
Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol (2007) 1.17
A review of adult mortality due to 2009 pandemic (H1N1) influenza A in California. PLoS One (2011) 1.17
The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses. J Virol (2011) 1.16
The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol (1983) 1.12
Cytokine production after influenza vaccination in a healthy elderly population. Vaccine (1998) 1.11
Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cell Immunol (2004) 1.09
NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine (2010) 1.08
Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol (2010) 1.07
Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine (2008) 1.04
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One (2009) 1.04
Limited expansion of virus-specific CD8 T cells in the aged environment. Mech Ageing Dev (2009) 1.04
Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J Virol (2009) 1.01
A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci (2006) 1.01
Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep (2010) 1.00
Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res (2009) 0.98
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine (2008) 0.96
Early priming minimizes the age-related immune compromise of CD8⁺ T cell diversity and function. PLoS Pathog (2012) 0.95
Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol (2004) 0.94
Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine (2011) 0.93
Natural killer cell function is altered during the primary response of aged mice to influenza infection. Mech Ageing Dev (2011) 0.93
CD8 T cell responses to influenza virus infection in aged mice. Ageing Res Rev (2011) 0.93
The murine thymic microenvironment: changes with age. Int Arch Allergy Immunol (1996) 0.92
Influenza-induced production of interferon-alpha is defective in geriatric individuals. J Clin Immunol (2010) 0.91
A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine (2011) 0.91
Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine (2011) 0.90
Chemokine production by natural killer cells from nonagenarians. Eur J Immunol (2002) 0.88
Transcriptome analysis of murine thymocytes reveals age-associated changes in thymic gene expression. Int J Med Sci (2009) 0.87
RANTES and MIP-1alpha production by T lymphocytes, monocytes and NK cells from nonagenarian subjects. Exp Gerontol (2002) 0.86
Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine (1990) 0.86
A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine (2000) 0.85
Specific immune responses but not basal functions of B and T cells are impaired in aged mice. Cell Immunol (2009) 0.83
Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. J Infect Dis (1993) 0.81
Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86. Vaccine (1998) 0.79
Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine (1998) 0.78
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog (2007) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog (2009) 6.09
Human host factors required for influenza virus replication. Nature (2010) 5.28
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog (2007) 4.99
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol (2006) 4.74
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85
High temperature (30 degrees C) blocks aerosol but not contact transmission of influenza virus. J Virol (2008) 3.77
Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science (2012) 3.74
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog (2005) 3.44
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol (2007) 3.04
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol (2006) 2.78
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol (2007) 2.62
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
The biology of influenza viruses. Vaccine (2008) 2.58
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Pause on avian flu transmission research. Science (2012) 2.24
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A (2006) 2.23
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol (2007) 2.18
Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis (2009) 2.12
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol (2012) 2.07
Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol (2007) 2.05
Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. Infect Disord Drug Targets (2007) 2.04
PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol (2010) 2.01
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Cellular proteins in influenza virus particles. PLoS Pathog (2008) 1.96
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol (2008) 1.95
Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol (2010) 1.92
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol (2012) 1.90
Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med (2013) 1.84
The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J Virol (2011) 1.82
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One (2012) 1.81
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol (2010) 1.72
Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Res (2003) 1.70
Unraveling the mystery of swine influenza virus. Cell (2009) 1.70
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol (2005) 1.69
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis. Proc Natl Acad Sci U S A (2012) 1.61
The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog (2011) 1.60
In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol (2013) 1.59
Transmission of a 2009 pandemic influenza virus shows a sensitivity to temperature and humidity similar to that of an H3N2 seasonal strain. J Virol (2010) 1.56
Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol (2009) 1.50
Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol (2009) 1.50
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med (2013) 1.49
Influenza A virus PB1-F2: a small protein with a big punch. Cell Host Microbe (2007) 1.49
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol (2013) 1.48
A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine (2007) 1.48
Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog (2010) 1.46
An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic (2005) 1.44
A single N66S mutation in the PB1-F2 protein of influenza A virus increases virulence by inhibiting the early interferon response in vivo. J Virol (2010) 1.44
Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination. PLoS Pathog (2012) 1.44
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A (2011) 1.42
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis (2012) 1.41
Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. J Virol (2012) 1.40
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun (2013) 1.37
A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF. J Virol (2008) 1.37
Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol (2011) 1.35
Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc Natl Acad Sci U S A (2013) 1.34
Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol (2015) 1.32
Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res (2008) 1.30
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Influenza virus protein PB1-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential. J Virol (2012) 1.29
Universal epitopes of influenza virus hemagglutinins? Nat Struct Mol Biol (2009) 1.29
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28